These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 16288376

  • 21. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
    Brans R, Yao F.
    BMC Microbiol; 2010 Jun 03; 10():163. PubMed ID: 20525279
    [Abstract] [Full Text] [Related]

  • 22. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
    Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study Group.
    N Engl J Med; 2002 Nov 21; 347(21):1652-61. PubMed ID: 12444179
    [Abstract] [Full Text] [Related]

  • 23. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M, Soleimanjahi H, Fotouhi F, Pakravan N.
    Comp Immunol Microbiol Infect Dis; 2009 Sep 21; 32(5):453-61. PubMed ID: 18571235
    [Abstract] [Full Text] [Related]

  • 24. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28228587
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
    Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, Miller G, Corey L.
    J Infect Dis; 2004 Oct 15; 190(8):1374-81. PubMed ID: 15378428
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
    Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH.
    Vaccine; 2012 Oct 12; 30(46):6541-6550. PubMed ID: 22947141
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
    Bernstein DI, Cardin RD, Bravo FJ, Hamouda T, Pullum DA, Cohen G, Bitko V, Fattom A.
    Vaccine; 2019 Oct 08; 37(43):6470-6477. PubMed ID: 31515143
    [Abstract] [Full Text] [Related]

  • 38. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits.
    Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL.
    Virology; 1998 Dec 05; 252(1):200-9. PubMed ID: 9875329
    [Abstract] [Full Text] [Related]

  • 39. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A, Merigan TC.
    J Immunol; 1988 Jan 01; 140(1):294-9. PubMed ID: 2826591
    [Abstract] [Full Text] [Related]

  • 40. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.
    Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI.
    J Infect Dis; 2000 Nov 01; 182(5):1304-10. PubMed ID: 11023454
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.